Trial Profile
Vargatef in 2nd-line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Docetaxel
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms VARGADO
- Sponsors Boehringer Ingelheim
- 14 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Results (n=219 As cut off date, December 1, 2022) of updated analysis of Cohort C focuses on the safety and efficacy of NIN + DOC according to programmed death ligand-1 (PD-L1) and KRAS status presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 23 Jan 2023 Planned End Date changed from 31 Dec 2024 to 31 Jan 2025.